Travere Therapeutics, Inc.

Total Valuation

Travere Therapeutics, Inc. carries a market capitalization of 5.26B, placing it among publicly traded companies globally. Its enterprise value stands at 2.74B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Travere Therapeutics, Inc. currently has 92.40M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 4.99, and the price-to-book ratio stands at -1.77.

Enterprise Valuation

On an enterprise value basis, Travere Therapeutics, Inc. trades at an EV/EBITDA multiple of 170.24 and an EV/FCF ratio of 23.08.

Financial Position

Travere Therapeutics, Inc. maintains a current ratio of 3.13, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 331.88, indicating elevated leverage, while an interest coverage ratio of 1.58 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Travere Therapeutics, Inc. has paid 829,000.00 in income taxes, reflecting an effective tax rate of 0.03.

Stock Price Statistics

Travere Therapeutics, Inc.'s stock has gained approximately 257.64855% over the past 52 weeks. The 50-day moving average sits at 50.96, while the 200-day moving average is 37.12.

Income Statement

Over the trailing twelve months, Travere Therapeutics, Inc. generated 536.20M in revenue and converted that into -21.42M in net income, yielding earnings per share of -0.49. EBITDA reached 16.09M, while operating income came in at -57.06M.

Balance Sheet

Travere Therapeutics, Inc. holds 264.68M in cash and equivalents against 327.66M in total debt, resulting in a net debt position of 233.72M. Total book value stands at -1.51B, with working capital of 267.24M providing operational flexibility.

Cash Flow

Travere Therapeutics, Inc. produced 39.61M in operating cash flow over the past twelve months. After subtracting -68.69M in capital expenditures, free cash flow totaled -29.08M - equivalent to -0.32 per share.

Margins

Travere Therapeutics, Inc. operates with a gross margin of 93.95, reflecting its pricing power and cost economics. The operating margin of -10.64 and net profit margin of -4.00 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Travere Therapeutics, Inc.'s most recent stock split took place on November 2, 2012 with a 9:1 split ratio.

Scores

Travere Therapeutics, Inc. posts an Altman Z-Score of 0.27, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.